Pramipexole

Generic Name: Pramipexole

Brand Names: Mirapex, Mirapexin, Sifrol, Pramipexole Teva, Oprymea

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N_₃S

CAS Number: 104632-26-0

Unique Ingredient Identifier: 83619PEU5T

Background: Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is one of the most common neurodegenerative disorders and...

Indication: This drug is indicated for the symptomatic treatment of Parkinson’s disease . This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) .

Associated Conditions: Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)

Associated Therapies: -

Clinical Trials

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Completed

Conditions: Parkinson Disease

Interventions: Drug: pramipexole

First Posted Date: 2011-05-26

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2017

Registration Number: NCT01361009

Locations: 🇨🇳
Boehringer Ingelheim Investigational Site 52, Suzhou, China
🇨🇳
Boehringer Ingelheim Investigational Site 57, Beijing, China
🇨🇳
Boehringer Ingelheim Investigational Site 60, Beijing, China

and more 100 locations

Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder

Phase 3

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: pramipexole
Drug: acetylsalicylic acid
Drug: placebo
Drug: minocycline

First Posted Date: 2011-03-23

Last Posted Date: 2011-03-23

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 400

Registration Number: NCT01320982

Locations: 🇷🇴
Clinica de Psihiatrie, Arad, Romania
🇷🇴
Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia", Bucuresti, Romania
🇷🇴
Sp. Jud. "Prof. Dr.O. Fodor", Cluj-Napoca, Romania

and more 4 locations

Pramipexole for Binge Eating Disorder

Phase 3

Withdrawn

Conditions: Binge Eating Disorder

Interventions: Drug: Pramipexole

First Posted Date: 2010-04-19

Last Posted Date: 2013-05-06

Lead Sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota

Registration Number: NCT01106053

Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole

Phase 4

Terminated

Conditions: Depression

Interventions: Drug: Pramipexole

First Posted Date: 2010-02-10

Last Posted Date: 2017-05-16

Lead Sponsor: Stanford University

Target Recruit Count: 16

Registration Number: NCT01066897

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Phase 4

Terminated

Conditions: Early-stage Parkinson's Disease

Interventions: Drug: Pramipexole
Drug: Rasagiline

First Posted Date: 2010-01-13

Last Posted Date: 2012-05-28

Lead Sponsor: Qualissima

Target Recruit Count: 112

Registration Number: NCT01048229

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Phase 3

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: placebo
Drug: pramipexole
Drug: pregabalin

First Posted Date: 2009-10-07

Last Posted Date: 2021-02-15

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 85

Registration Number: NCT00991276

Locations: 🇺🇸
Pfizer Investigational Site, Dallas, Texas, United States

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Phase 2

Terminated

Conditions: Advanced Stage Parkinson's Disease

Interventions: Drug: pardoprunox
Drug: pramipexole

First Posted Date: 2009-05-18

Last Posted Date: 2011-08-26

Lead Sponsor: Abbott Products

Target Recruit Count: 37

Registration Number: NCT00903838

Locations: 🇮🇹
Site Reference ID/Investigator# 45435, Cassino, Italy
🇮🇹
Site Reference ID/Investigator# 45436, Chieti Scalo, Italy
🇩🇪
Site Reference ID/Investigator# 45422, Tuebingen, Germany

and more 6 locations

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Phase 3

Completed

Conditions: Idiopathic Restless Legs Syndrome

Interventions: Drug: pramipexol
Drug: placebo and pregabalin
Drug: Pregabalin

First Posted Date: 2008-12-10

Last Posted Date: 2021-01-26

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 731

Registration Number: NCT00806026

Locations: 🇬🇧
Pfizer Investigational Site, Reading Berks, United Kingdom

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease

First Posted Date: 2008-04-25

Last Posted Date: 2008-04-25

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 13

Registration Number: NCT00666653

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

Phase 3

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Pramipexole
Drug: Placebo

First Posted Date: 2008-04-08

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 306

Registration Number: NCT00654498

Locations: 🇨🇳
248.630.06 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳
248.630.07 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳
248.630.01 Boehringer Ingelheim Investigational Site, Shanghai, China

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy